Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
Mäkelä E, Pavic K, Varila T, Salmenniemi U, Löyttyniemi E, Nagelli SG, Ammunét T, Kähäri VM, Clark RE, Elo LL, Bachanaboyina VK, Lucas CM, Itälä-Remes M, Westermarck J.
Mäkelä E, et al. Among authors: clark re.
Clin Cancer Res. 2021 May 15;27(10):2848-2860. doi: 10.1158/1078-0432.CCR-20-3679. Epub 2021 Mar 5.
Clin Cancer Res. 2021.
PMID: 33674272